Incyte Corporation

NASDAQ:INCY

Biotechnology

Healthcare
$117.80 -0.78%

-$0.77 today

Market cap
$24.01B
Beta
0.79
P/E (TTM)
13.7
EPS (TTM)
$7.18
52W Low $66.74High $112.29

Volume 1.21M

Average 1.58M

INCY Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Incyte CorporationNASDAQ: INCY

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit growth accelerates

Q2 FY2026 gross profit of $1.57B rose 38.0% year over year, ahead of the +26.6% change in trailing-twelve-month gross profit. Sequentially, it rose 34.3% from the prior quarter. Over 3 fiscal years it compounded at +14.4% a year.

Context

  • Gross profit amounted to 92.8% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +38.0% holds above the trailing-twelve-month pace of +26.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.57B+34.3% QoQ
Last fiscal yearDec 2025
$4.77B+21.4% YoY
LTMJun 2026
$5.39B+26.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+38.0%——
1 year+21.4%——
3-year CAGR+14.4%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
4.77B USD
Year-over-year change
+21.4%
4-year CAGR
+13.9%

Gross Profit vs competitors

How INCY compares with its peers on the latest reported figures

  • INCY's LTM Jun 2026 gross profit of $5.39B is the 2nd highest of the 11 companies compared; the peer median is $446.8M.
  • Its year-over-year change of +26.6% is the 5th highest of 8, against a peer median of +40.6%.
  • Gross profit amounts to 92.6% of revenue for INCY, versus a peer median of 86.5%.
INCY Competitors Peer median
Gross Profit for INCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$13.18B +8.4%+5.4%84.9%
INCYIncyte CorporationLTM Jun 2026$5.39B +26.6%+14.4%92.6%
GMABGenmab A/SLTM Jun 2026$3.84B —-38.3%93.0%
EXELExelixis, Inc.LTM Jul 2026$2.35B +9.1%+12.9%96.5%
LEGNLegend Biotech CorporationLTM Sep 2026$774.12M +40.6%+129.1%57.0%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$607.18M +545.5%—86.5%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$286.42M +74.1%+22.2%98.6%
VSTMVerastem, Inc.LTM Mar 2026$41.53M +315.3%+114.5%83.7%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 ———
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 ———
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$79K -2.6%——
Peer median (excluding INCY) $446.8M+40.6%+17.5%86.5%

Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.99B3.39B3.7B4.24B5.14B
Cost of Revenue150.99M207M254.99M312.1M372.1M
Gross Profit2.84B3.19B3.44B3.93B4.77B
Gross Margin94.9%93.9%93.1%92.6%92.8%
Research & Development1.46B1.59B1.63B2.61B2.05B
Selling, General & Admin739.56M1B1.16B1.22B1.38B
Operating Expenses2.25B2.6B2.79B3.83B3.43B
Depreciation & Amortization57.84M67.86M82.66M89.25M93.29M
EBITDA630.2M599.64M919.43M408.16M1.76B
EBITDA Margin21.1%17.7%24.9%9.6%34.2%
Operating Income585.78M591.63M655.36M101.29M1.34B
Operating Margin19.6%17.4%17.7%2.4%26.1%
Interest Income000128.71M105.6M
Interest Expense1.91M2.67M2.55M2.28M2.43M
Other Income / Expenses(15.33M)(62.51M)178.86M215.34M321.66M
Income Before Tax570.44M529.12M834.22M316.63M1.66B
Pre-Tax Margin19.1%15.6%22.6%7.5%32.4%
Income Tax Expense(378.14M)188.46M236.62M284.02M377.8M
Net Income948.58M340.66M597.6M32.62M1.29B
Net Margin31.8%10.0%16.2%0.8%25.0%
EPS (Basic)4.301.532.670.166.59
EPS (Diluted)4.271.522.650.156.41
Weighted Avg Shares220.43M222M223.63M207.11M195.2M
Weighted Avg Shares (Diluted)222.07M223.96M225.93M210.53M200.7M

Incyte Corporation

NASDAQ:INCY

Intrinsic Alpha fair value

Locked

Current Price

$117.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.